Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...